Spirair
South San Francisco, California, United States · Biotechnology, Health Care, Medical · 35 employees
Spirair is an early-stage company pioneering minimally invasive solutions for ENTs to advance care for their patients. The company is dedicated to developing a novel therapy for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septum with a bioabsorbable implant.
Funding history
- Venture - Series Unknown — $24.7M — Mar 2026
- Venture - Series Unknown — $24.7M — Aug 2025
Recent signals
- Mar 10, 2026: Raised $24.7M in Venture - Series Unknown
- Aug 12, 2025: Raised $24.7M in Venture - Series Unknown
See plans & pricing → Track Spirair’s funding, hiring, and signals — with verified contacts — on Fundz.